Oncology Books

Book SynopsisThere has been an exponential increase in the volume and quality of published research relating to breast disease over the past decades. This book identifies the 50 key scientific articles in the field of breast disease and breast surgery and examines their importance and impact on current clinical care.Among thousands of articles, a small fraction are truly ''game changing''. Such studies form the foundations of breast surgery today, and the selection of papers within this book provide the 50 landmark papers every 21st-century breast surgeon needs to know. A commentary to each carefully selected paper explains why these papers are so important, thus providing every surgeon with the foundation stones of knowledge in this fast-moving area.A valuable reference not only to the established surgeon, but also to breast surgery residents and trainees, as well as to more experienced surgeons as they continue to learn new techniques and approaches and to improve their knowledge

Read more less

Book SynopsisThis fully updated volume explores recently improved avenues to study urothelial carcinomas.Table of ContentsPart I: Molecular Characterization 1. Scoring Systems for Immunohistochemistry in Urothelial Carcinoma Mark-Sebastian Bösherz, Iryna V. Samarska, and Nadine Therese Gaisa 2. A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer Csilla Olah and Tibor Szarvas 3. Analysis of Mutational Signatures Using the mutSignatures R Library Damiano Fantini and Joshua J. Meeks 4. A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures Marika Mokou, Shaman Narayanasamy, Rafael Stroggilos, Irina-Afrodita Balaur, Antonia Vlahou, Harald Mischak, and Maria Frantzi 5. Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography Christoph Peter, Wolfgang A. Schulz, and Patcharawalai Whongsiri Part II: Urothelial Carcinogenesis 6. Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview Lancelot Seillier and Martin Peifer 7. Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells Theodoros Rampias and Apostolos Klinakis 8. Identification of STAG2 Mutant Bladder Cancers by Immunohistochemistry Youngrok Park, Alana Lelo, Brent Harris, Deborah L. Berry, Krysta Chaldekas, Jung-Sik Kim, and Todd Waldman Part III: Cellular and Animal Models 9. Genome-Wide CRISPR Screening for the Identification of Therapy-Resistance-Associated Genes in Urothelial Carcinoma Klaus Mantwill and Roman Nawroth 10. Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma William Donelan, Paul L. Crispen, and Sergei Kusmartsev Part IV: Biomarkers 11. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA Iver Nordentoft, Karin Birkenkamp-Demtröder, and Lars Dyrskjøt 12. Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-Muscle Invasive Bladder Cancer Thorsten H. Ecke, Natalya Benderska-Söder, Ekkehardt Bismarck, Bas W.G. van Rhijn, Tilman Todenhöfer, and Bernd J. Schmitz-Dräger 13. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-Invasive Diagnosis of Urothelial Cancer Maria Zvereva, Md Ismail Hosen, Nathalie Forey, Mahdi Sheikh, Caroline Kannengiesser, Ibrahima Ba, Arnaud Manel, Emmanuel Vian, and Florence Le Calvez-Kelm 14. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer Jussi Nikkola and Peter Black 15. Assessment of PD-L1 Status in Urothelial Cancer Veronika Bahlinger, Arndt Hartmann, and Markus Eckstein Part V: Therapy Development 16. Epigenetic Priming and Development of New Combination Therapy Approaches Sarah Meneceur, Camilla M. Grunewald, Günter Niegisch, and Michèle. J. Hoffmann 17. Evaluation of FGFR Alteration Status in Urothelial Tumors Veronika Bahlinger, Markus Eckstein, Arndt Hartmann, and Robert Stöhr 18. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma Günter Niegisch 19. Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer Paola Grandi, Andrea Darilek, Anay Moscu, Anu Pradhan, and Roger Li 20. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21 Kate Relph, Mehreen Arif, Hardev Pandha, Nicola Annels, and Guy R. Simpson

Read more less

Book SynopsisThe Role of the Clinical Nurse Specialist in Cancer Care Gain a fresh and insightful perspective on the evolving role of the Clinical Nurse Specialist in the delivery of cancer services. The Role of the Clinical Nurse Specialist in Cancer Care explores the dynamic and essential world of the Clinical Nurse Specialist (CNS) in cancer care, covering both foundational and advanced topics and rooted in robust research and evidence-based practice. Trace the historical development of the CNS role while gaining invaluable patient and carer perspectives that provide essential guidance for professionals in this fieldExamine key aspects such as symptom management and non-medical prescribing, gaining a deeper understanding of the multifaceted responsibilities of Clinical Nurse SpecialistsFind vital subjects like leadership and multidisciplinary teamwork supplemented with practical tools to excel in your roleExplore comprehensive coverage of specialised areas within clinical nursing, including the unique challenges of caring for young adults with cancer, navigating the complexities of COVID-19, and utilising digital tools for enhanced patient care Whether you are a registered nurse aspiring to become a clinical nurse specialist or an established CNS seeking professional growth, The Role of the Clinical Nurse Specialist in Cancer Care provides invaluable insights and development opportunities. This engaging resource is also an excellent companion for advanced practitioners specialising in cancer care, ensuring they stay up-to-date with the latest advancements in this vital field.Table of ContentsList of Contributors xiv Foreword xvi Introduction xviii About the Companion Website xxi 1 Evolvement of Advanced Nursing Practice 1 Helen Kerr 1.1 Introduction 1 1.2 Evolvement of Nursing as a Profession 1 1.3 Advanced Nursing Practice 3 1.3.1 Criteria Associated with Advanced Nursing Practice 4 1.3.2 Advanced Practice Nurse Roles 6 1.3.3 Regulation 8 1.3.4 Components of Advanced Practice Nurse Roles 8 1.3.5 Education Requirements 8 1.3.6 Outcomes Associated with Advanced Practice Nurse Roles 9 1.3.7 Barriers to Advanced Practice Nursing Roles 9 1.3.8 Recommendations for Advanced Practice Nurse Roles 10 1.4 Conclusion 10 References 11 2 Emergence and Evolvement of the Clinical Nurse Specialist Role in Cancer Care 15 Helen Kerr 2.1 Introduction 15 2.2 Advanced Nursing Practice 15 2.3 Historical Context 16 2.4 Specialists vs. Generalists 17 2.5 Definition of a CNS 18 2.5.1 Role Blurring 18 2.6 Components of the Clinical Nurse Specialist Role 19 2.6.1 Direct Patient Care 20 2.6.2 Indirect Care 20 2.7 Professional Standards 21 2.8 Education Requirements 22 2.8.1 Impact of a Master’s Qualification 22 2.9 Outcomes of the Clinical Nurse Specialist Role 23 2.9.1 Outcomes Associated with the Clinical Nurse Specialist in Cancer Services 24 2.10 Specialist Practice in Cancer Care 25 2.11 Future Direction of the CNS 25 2.12 Conclusion 25 References 26 3 Patient Perspective 31 Johanna McMullan References 40 4 Carer’s Perspective 43 Trevor Wightman 5 Key Worker Role 49 Karen Armstrong and Helen Kerr 5.1 Introduction 49 5.2 The Key Worker 50 5.2.1 Provision of Information 52 5.2.2 Provision of Emotional and Supportive Care 52 5.2.3 Coordination of Services 53 5.3 Key Worker/Clinical Nurse Specialist Impact on Direct and Indirect Patient Care 54 5.4 Challenges in Practice 55 5.5 ‘First Impressions Count’ 57 5.6 Example of Change in Practice 58 5.7 Conclusion 59 References 59 6 Psychological Support 63 Caroline McCaughey, Edel Aughey, and Susan Smyth 6.1 Introduction 63 6.2 Part One: The Impact of a Cancer Diagnosis 64 6.2.1 Time Point One: Breaking Significant News 66 6.2.2 Time Point Two: Treatment Decision-Making 70 6.2.3 Time Point Three: Survivorship and Resilience 71 6.2.4 Fear of Recurrence 73 6.3 Part Two: Self-Care and the Clinical Nurse Specialist 74 6.4 Conclusion 77 References 78 7 Integrating Research and Evidence-Based Practice 84 Adrina O’Donnell, Ruth Boyd, and Clare McVeigh 7.1 Introduction 84 7.2 Evidence-Based Practice 85 7.3 Barriers to the Implementation of Evidence-Based Practice in the Clinical Setting 86 7.4 Role of Evidence-Based Practice in Caring for Patients with Cancer and Their Carers 87 7.5 Providing Evidence-Based Care as a Clinical Nurse Specialist 87 7.6 Clinical Application of Evidence-Based Practice by Clinical Nurse Specialists 88 7.7 Cancer Research and Clinical Trials 89 7.8 Cancer Clinical Trials, Research Nurses and the Role of the Clinical Nurse Specialist 91 7.9 The Role of the Clinical Nurse Specialist Along the Cancer Clinical Trial Patient Pathway 92 7.10 Conclusion 97 References 98 8 Symptom Management 104 Michelle Keenan and Helen Kerr 8.1 Introduction 104 8.2 Pain 105 8.2.1 Renal Impairment 107 8.2.2 Hepatic Impairment 108 8.2.3 Neuropathic Pain 109 8.3 Breathlessness 110 8.4 Nausea and Vomiting 112 8.5 Constipation 115 8.6 Conclusion 115 References 116 9 Multidisciplinary Teamworking 124 Hinal Patel and Oonagh McSorley 9.1 Introduction 124 9.2 The Multidisciplinary Team 125 9.2.1 Characteristics of an Effective Multidisciplinary Team 126 9.2.1.1 The Team 126 9.2.1.2 Multidisciplinary Meeting Organisational Logistics 128 9.2.1.3 Infrastructure for the Multidisciplinary Meeting 128 9.2.1.4 Person-Centred Clinical Decision-Making 128 9.2.1.5 Team Governance 129 9.3 The Role of the Clinical Nurse Specialist in Relation to the Multidisciplinary Team 129 9.3.1 Challenges of the Clinical Nurse Specialist Working in a Team 130 9.4 Conclusion 132 References 133 10 Leadership and the Clinical Nurse Specialist 136 Ruth Thompson and Monica Donovan 10.1 Introduction 136 10.2 Leadership 137 10.3 Self-Recognition of the Clinical Nurse Specialist as a Leader 137 10.4 Leadership in the Context of the Clinical Nurse Specialist 139 10.4.1 Clinical Leadership 140 10.4.1.1 Clinical Expertise and Coordination of Care 141 10.4.2 Professional Leadership 142 10.4.2.1 Enhancing Practice 143 10.4.2.2 Service Improvement and Innovation 143 10.4.2.3 Collaborative Working 144 10.5 Conclusion 144 References 144 11 Nurse-Led Clinics 149 Shelley Mooney and Helen Kerr 11.1 Introduction 149 11.2 Nurse-Led Care and the Launch of Nurse-Led Clinics in Healthcare 150 11.3 Components of a Nurse-Led Clinic 151 11.4 Introducing a Nurse-Led Clinic 152 11.5 Nursing Skills Required to Introduce and Establish a Nurse-Led Clinic 154 11.6 Approaches to Delivering a Nurse-Led Clinic 155 11.7 Patient Outcomes Related to Nurse-Led Clinics 156 11.8 Benefits of Nurse-Led Clinics for the Registered Nurse 157 11.9 Benefits of Nurse-Led Clinics for the Healthcare Organisation 157 11.10 Challenges to Implementing Nurse-Led Clinics 158 11.11 Nurse-Led Clinic Service Evaluation 159 11.12 Future of Nurse-Led Clinics 159 11.13 Reflection on the Role as a Uro-Oncology CNS Undertaking Nurse-Led Clinics 160 11.14 Conclusion 161 References 162 12 Non-Medical Prescribing 166 Laura Croan and Barry Quinn 12.1 Introduction 166 12.2 Background 167 12.3 Developments in Nursing Practice and the Role of Prescribing 168 12.3.1 Community Nurse Prescribing 168 12.3.2 Clinical Management Plans 169 12.3.3 Patient Group Directives 169 12.3.4 The Growth of Independent Prescribing 170 12.4 Preparing to Prescribe 172 12.5 Benefits and Challenges of Non-Medical Prescribing 172 12.6 Deciding to Become a Non-Medical Prescriber 173 12.7 Conclusion 177 References 178 13 Cancer in the Adolescent and Young Adult 181 Kerrie Sweeney and Helen Kerr 13.1 Introduction 181 13.2 Background to Adolescent and Young Adult Cancer Services 182 13.3 Person-Centred Adolescent and Young Adult Care 185 13.4 Support for Family and Significant Others 185 13.5 Holistic Care 186 13.6 Multidisciplinary Working 187 13.7 Healthcare Professional Knowledge 188 13.8 Adolescent and Young Adult Clinical Nurse Specialist Leadership Skills 189 13.9 Communication with Adolescents and Young Adults 189 13.10 Age-Appropriate Environments 191 13.11 Adolescent and Young Adult Peer Support 192 13.12 Adolescent and Young Adult Treatment Priorities 192 13.13 Transitional Adolescent and Young Adult Care 193 13.14 Living With and Beyond Cancer 194 13.15 Late Effects of Cancer Treatment 195 13.16 Palliative Adolescent and Young Adult Care 195 13.17 Co-production 196 13.18 Conclusion 196 References 197 14 COVID-19 and the Clinical Nurse Specialist 203 Stephanie Todd and Helen Kerr 14.1 Introduction 203 14.2 Impact on Healthcare Services and Frontline Healthcare Workers 204 14.3 Impact of COVID-19 on Cancer Services 205 14.4 The Role of the Clinical Nurse Specialist Prior to the COVID- 19 Pandemic 207 14.5 Devolvement of Staff over the COVID-19 Pandemic 208 14.6 Impact of COVID-19 on the Clinical Nurse Specialist Role and Patient Care 209 14.7 The Future of Healthcare Services Post–COVID-19 Pandemic 212 14.8 Conclusion 213 References 214 15 Digital Health 218 Amy Vercell and Sarah Hanbridge 15.1 Introduction 218 15.2 The Role of the Informatics Nurse/Chief Nursing Information Officer 220 15.3 Electronic Observations 220 15.4 Electronic Health Records 221 15.5 Digitalisation of Blood Glucose Monitoring 222 15.6 Electronic Nurse Prescribing 223 15.7 Nurse Digitally Requesting Bloods 224 15.8 Remote Consultations 224 15.9 Virtual Wards 225 15.10 Electronic Patient-Reported Outcome Measures 226 15.11 Mobile Cancer Applications 227 15.12 Home Blood Monitoring 228 15.13 Artificial Intelligence 229 15.14 Barriers to Digital Health 230 15.15 Conclusion 230 References 231 16 Future Direction of the Clinical Nurse Specialist in Cancer Care 236 Barry Quinn and Helen Kerr 16.1 Introduction 236 16.2 The Role of Caring and the Clinical Nurse Specialist 238 16.3 Developing Skills for Today and the Future 239 16.4 Leadership 240 16.5 Equality, Diversity and Inclusion in the Role of the Clinical Nurse Specialist 242 16.6 New Ways of Working 244 16.7 Self-Reflection 246 16.8 Conclusion 246 References 247 Index 250

Read more less

Book SynopsisFor those of us who have labored in the field of hormonal carcinogenesis, it has been most gratifying to see its rapid growth and increasing relevance in recent years. Although many factors and forces have contributed to this phenomenon, a few appear particularly significant. Perhaps foremost is the realization that two of the most prevalent cancers which afflict women and men; that is, breast and prostate, have essential hormonal component(s) to their etiologies. This should not surprise us since the high frequency of these cancers in human populations has to date not been attributed to any exogenous physical, environmental, or dietary factor(s). A similar argument may be applied to other less prevalent but equally important cancers including ovarian, endometrial, testicular, cervico vaginal, pituitary, thyroid, and sex hormone-associated hepatic neoplasms. The Office of ResearcTable of ContentsIntroductions.- Introductory Remarks.- Opening Address Important Questions in Women’s Health Research: Determining the Influence of Hormones on Health.- Symposium Presentations Mammary Carcinogenesis: A Unifying Hypothesis.- Regulation of Cytochrome P-450 and Carcinogenesis: Peroxisome Proliferator-Activated Receptor and Dioxin Receptor.- State Of The Art Lectures.- 1 Cell Cycle and Cell Proliferation.- 2 Role of a Cell Cycle Regulator in Hereditary and Sporadic Cancers.- 3 Molecular Cytogenetics of Solid Tumor Progression.- 4 Nucleocytoplasmic Shuttling of Estrogen Receptors Is Blocked by “Pure Antiestrogens”.- I. Epidemiology: Hormonal Cancers.- Causality in Hormone Associated Human Cancers.- 5 Breast Cancer Incidence in Women Exposed to Estrogen and Estrogen-Progestin Replacement Therapy.- 6 Breast Cancer Trends in Women in Sweden, the UK, and the USA in Relation to Their Past Use of Oral Contraceptives.- 7 Gene Expression in Familial Breast Cancer: A Genetic-Epidemiology Study of Premenopausal, Bilateral Breast Cancer.- 2. Breast/Mammary Gland.- The Importance of Human Breast Development in Mammary Carcinogenesis.- 8 Breast Susceptibility to Carcinogenesis.- 9 Hormones, Growth Factors and Gene Expression in Preneoplasias of the Mouse Mammary Gland.- 10 Pathogenesis of Ductal and Lobular Progestin-Induced Mammary Carcinomas in BALB/c Mice.- 3. Endometrium/Uterus.- 11 Is the hsp90 Connection Between Steroid Receptors and Immunosuppressant Binding Immunophilins Involved in the Control of Gene Transcription and Cell Growth?.- 12 Expression and Regulation of 17?-Hydroxysteroid Dehydrogenase Type 1 in Steroidogenic Cells and Estrogen Target Tissues.- Growth Factors in Endometrial Cancer.- 4. Kidney.- 13 Introduction Estrogens and Genitourinary Cancers of Syrian Hamsters.- 14 Interstitial Cell Origin of Estrogen-Induced Kidney Tumors in the Syrian Golden Hamster.- 15 Effects of Estrogens on Microtubule Assembly: Significance for Aneuploidy.- 16 Estrogen Carcinogenesis: A Sequential, Epi-Genotoxic, Multi-Stage Process.- 5. Liver.- Role of Estrogens in Liver Carcinogenesis.- 17 Hormonal Regulation of Hepatic Cell Proliferation and Apoptosis: Implications for Carcinogenesis.- 18 Mechanisms of Tamoxifen-Induced Genotoxicity and Carcinogenicity.- 19 Regulation of Growth-Associated Nuclear Transcription Factors During Growth Hormone-Regulated, Sex Differentiated Rat Liver Carcinogenesis.- 6. Prostate.- 20 Isolation of Differentially Expressed cDNAs from Prostate Cancer Cell Lines Using Differential Display PCR: Identification of an Androgen-Regulated Gene.- 21 Progression of LNCaP Human Prostate Carcinoma Cells: Androgen Receptor Activity and c-myc Gene.- 22 Regulation of Prostatic Growth and Gene Expression: Role of Stroma.- Concluding Remarks.- 23 Sex Hormones and Neoplastic Transformation.- CLINICAL FORUM: Risk and Benefits of Hormone Replacement Therapy and Oral Contraceptive Use.- Therapeutic Implications of Hormone Replacement Therapy and Oral Contraceptives.- 24 Postmenopausal Estrogen-Progestin Therapy in Relation to Cancers of the Endometrium and Breast.- 25 The Use of Hormone Replacement Therapy in Women Previously Treated for Breast Cancer.- 26 Cardioprotection by Hormone Replacement Therapy.- 27 Risk and Benefits of Oral Contraceptives.- 28 Oral Contraceptives and the Risk of Breast and Cervical Cancer.- Communications Session I. Epidemiology, Human Studies.- Some Aspects of Breast Cancer Epidemiology.- Risk of Breast Cancer Associated with Induced Abortion.- Family History of Breast Cancer as a Modifier of Other Risk Factors.- Oral Contraceptive Use and Reproductive Risk Factors for Breast Cancer: A Comparison of Results among Black and White Women.- Patterns of Cancer Mortality in Women Who Had Used Sex Steroid Hormones under Age 60.- Progestogen Use and Risk of Breast Cancer.- Five-Year Survival of Women with Breast Cancer According to Prior Use of Oral Contraceptives.- Plasma Prolactin and IGF-1 Levels in Young, Healthy, Nulliparous Women in Relation to Low Dose Oral Contraceptive Use.- Effect of a Low-Fat Diet on Estrogen and Bile Acid Metabolism in Normal Human Subjects.- Expression of GST? in Breast Cancer and its Relationship with the Expression of Estrogen Receptor and Progesterone Receptor.- p53 and Neu (c-erbB-2) Overexpression in Relation to Risk Factors for Breast Cancer.- Cost Effectiveness of Hormone Replacement Therapy in French Postmenopausal Women.- Tamoxifen Treatment Does Not Induce Endometrial Hyperplasia in Postmenopausal Women.- Uterine Myomas: A Model to Study Hormonal Regulation of Growth Related Genes.- Transforming Growth Factor ?1 Facilitates Cell Proliferation and Invasion in MAT-LyLu Prostatic Cancer Cells.- Quantitative Effects of Antiandrogen Therapy on High-Grade Prostatic Intraepithelial Neoplasia in Radical Prostatectomy Specimens.- Alterations in Circulating Levels of Androgens and PSA During Treatment with Finasteride in Men at High Risk for Prostate Cancer.- Session II. Cell & Molecular Biology, Metabolism.- Effect of Estradiol on MCF-7 Human Breast Cancer Cells: Ultrastructural Studies.- Estradiol and Tamoxifen Induce TGF-?l Gene Expression in Cultured Normal Human Breast Stromal Cells.- Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells.- Evaluation of Conformational Changes in hER-HBD by Pharmacological Dissection of Hormone Dissociation Rates in a Homogeneous Hormone-Binding Assay.- Estradiol Promotion of Size and Number of Hepatic Enzyme-Altered Foci in Rats in the Absence of Cell Proliferation.- Expression of Liver-Enriched Transcription Factors During Progression in the Resistant-Hepatocyte Model.- Nuclear Protein Binding to the AP-1 and CRE Sites During Sex-Differentiated Promotion of Rat Liver Carcinogenesis.- Induction of Endometrial Cancer by Tamoxifen in the Rat.- Mechanisms of Anti-Estrogen and Retinoid Inhibition of Breast Cancer Cell Proliferation.- Bisphenol-A Disturbs Microtubule Assembly and Induces Micronuclei In Vitro.- Natural Estrogens Induce Modulation of Microtubules in Chinese Hamster V79 Cells in Culture.- Induction of Micronucleation, Spindle Disturbances, and Mitotic Arrest in Human Chorionic Villi Cells by 17?-Estradiol, Diethylstilbestrol, and Coumestrol.- Increased Nuclear IGF-I Receptor Level, Coupled with Attenuation in DNA Repair, Plays an Important Role in Estrogen-Induced Carcinogenesis.- Pattern of Reproductive Aging in Female Rats Can Affect Mammary Tumor Incidence.- Antiproliferative Activity of Luteolin, a Naturally-Occurring Edible Plant Flavone, Against Estrone-Induced Cell Proliferation in the Mammary Gland of Noble Rats.- Sex Hormone-Induced Prostatic Carcinogenesis in Noble Rats Involves Genetic Damage and Cell Proliferation.- Catechol Estrogen Analogs as Probes of Estrogen Carcinogenesis.- In-Vitro Metabolites of Coumestrol.

Read more less

Book SynopsisManagement of Soft Tissue Sarcoma addresses the diagnosis and best current management of adult soft tissue sarcomas. Both clinical and molecular diagnoses are addressed, and tumor histopathology is employed as the basis of treatment recommendations including surgery, radiation therapy, systemic therapy and novel therapeutics.Trade Review“This is an excellent monograph of the Diagnosis, Pathology, Imaging, Treatment, and Surgical outcomes of sarcomas and related tumors of the soft tissue variety. … This is a very good book for oropedic surgeons, patologists, students, and clinicians with an interest in the diagnosis and treatment of high and low grade liposarcomas, leomyosarcomas, benign type lesions, and other kind of subcutaneous tumors with distant lung, brain, and liver metastases.” (Joseph J. Grenier, Amazon.com, October, 2015)“This is an impressive book. Written by a surgeon, a pathologist and an oncologist, the book draws heavily on the Memorial Sloan-Kettering Cancer Center soft tissue sarcoma (STS) database. … it is a book that should be in the library of any sarcoma unit and will appeal to the sub-specialist in Orthopaedic Oncology.” (Robert U. Ashford, European Journal of Orthopaedic Surgery & Traumatology, Vol. 24, 2014)“The book is laid out in 27 chapters, with an impressive inclusion of a wide array of sarcoma histology. One of the real strengths of the book is the quality and number of images, figures, tables, and graphs. … The overall outline of the text is well done. … This book is a unique and important addition to the sarcoma literature. … this edtion should find itself on every medical oncologist’s bookshelf … .” (Larry C. Daugherty and Sanjay P. Bagaria, Journal of Radiation Oncology, Vol. 3, 2014)Table of ContentsPrefaceIntroduction 1. General Description2. Natural History – Importance of Size, Site, Histopathology3. General Statement as to Efficacy of Surgery / Chemotherapy / Radiation Therapy Part I. Management by Histopathology - Introduction4. Gastrointestinal Stromal Tumor (GIST)5. Liposarcoma 6. Leiomyosarcoma 7. Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma - MFH) / Myxofibrosarcoma 8. Synovial Sarcoma 9. Malignant Peripheral Nerve Sheath Tumor (MPNST) / Triton Tumor10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions2. Natural History – Importance of Size, Site, Histopathology3. General Statement as to Efficacy of Surgery / Chemotherapy / Radiation Therapy Part I. Management by Histopathology - Introduction4. Gastrointestinal Stromal Tumor (GIST)5. Liposarcoma 6. Leiomyosarcoma 7. Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma - MFH) / Myxofibrosarcoma 8. Synovial Sarcoma 9. Malignant Peripheral Nerve Sheath Tumor (MPNST) / Triton Tumor10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions

Read more less

Book Synopsis1. Human Papillomaviruses and Cancer: A Retrospective.- 2. Regulation of E6 and E7 Oncogene Transcription.- 3. E6 Protein.- 4. E7 Protein.- 5. Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention.Table of Contents1. Human Papillomaviruses and Cancer: A Retrospective.- 2. Regulation of E6 and E7 Oncogene Transcription.- 3. E6 Protein.- 4. E7 Protein.- 5. Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention.

Read more less

Book SynopsisPart of the popular Biopsy Interpretation Series, Biopsy Interpretation of the Skin: Primary Non-Lymphoid Cutaneous Neoplasia, Second Edition , is a concise, practical resource with a strong focus on diagnosis. It offers guidelines on how and when to biopsy the skin and provides superb coverage of common and uncommon non-lymphoid neoplasms of the skin. Focusing on the daily tasks and needs of the general pathologist, this updated Second Edition is an excellent bench reference and education resource for the interpretation of the most common skin biopsies. Incorporates recent advances in the biology of skin cancer which have led to important biologic therapies for melanoma, basal cell carcinoma, and squamous cell carcinoma. Includes new chapters on the clinical approach to surgical conditions of the skin and soft tissue tumors. Offers online access to 375 additional figures, plus an online multiple-choice test bank that is ideal for board exam preparat

Read more less

Book SynopsisThis unique synthesis of chapters from top experts in their fields, targets the very important and upcoming area of cancer biomarkers and the need for better and more rigorous design and clinical trial. The book covers several aspects of cancer molecular markers from innovation, screening, controversies and future directions. The primary target audience for the book includes PhD and MD students, researchers, biologists, medical doctors and professionals who are interested in mechanistic studies on cancer diagnosis and translational benefits from personalized cancer treatment using the new era of biomarkers.Table of ContentsImproving Research on Biomarkers for Early Detection and Screening of Cancers. Biomarkers of Oxidative Stress in Carcinogenesis. ß-Catenin: a Novel Biomarker and Therapeutic Target in Liver Cancer. Urine Biomarkers for Prostate Cancer Detection. Ectodomain Shedding as a Mechanism to Generate Cancer Biomarkers (Ectomarkers). The BRCT Signaling ‘landscape’: Emerging Concepts and Implications in Tumorigenesis and Cancer Diagnostics. Cellular Senescence and Cancer Development: Antagonistic and Synergistic Relations. Micro-RNAs: From Regulators of Gene Expression to Cancer Biomarkers. Targeting PARP-1 in Breast Cancer: The Paradigm of a DNA Repair-based Therapeutic Strategy. Statins in Prostate Cancer: Prevention and Treatment. Mechanistic Aspects of Oxidative Stress Involvement in Human Environmental and Occupational Carcinogenesis.

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisCan you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions. This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of American Media.Trade ReviewThis is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. It will be useful, not just for the lay reader, but also for therapists and others with a scientific background. --G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of American Media. If you are ever diagnosed with advanced cancer, the odds are very good that your oncologist will tell you that unless you immediately consent to chemotherapy you are going to die. This is a lie! I know, I have been treating conventional chemotherapy failures for years. Other than for leukemia or lymphoma, conventional chemotherapy is almost always a death sentence. There are so many more effective ways to treat advanced cancer, and Dr. Carl Helvie's book, You Can Beat Lung Cancer: Using Alternative/Integrative Interventions, describes some of the most effective. In addition, his book is packed with references and information sources that will help anyone fighting cancer learn more about how to go about it successfully. --Frank Shallenberger, MD, HMD, ABAAM, Medical Director, The Nevada Center of Alternative Medicine, Editor: Real Cures Newsletter and Author This is a valuable piece of writing, to give people hope that there are other ways back to health from cancer, than the 'slash, burn and poison' offered by conventional oncology. --Robert A. Eslinger, D.O., H.M.D. | Medical Director, Reno Integrative Medical Center

Read more less

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer provides a practical overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Dr. Milind Javle of MD Anderson Cancer Center and Dr. Mitesh J. Board of Mayo Clinic helps you filter and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents. Covers gastrointestinal cancer targets—stage 1, 2, and 3 trials and preliminary results, as well as approved therapies. Includes sections on Sequencing Technologies, and Targeted and Immunotherapy Agents. Organizes information by tumor type, pathway, and drug name, so you can approach clinical challenges from any direction. Highlights FDA approvals throughout. Pocket-sized and color coded to help you find information quickly and easily. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,

Read more less

Book SynopsisWritten by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference. Discusses the multitude of complex adverse effects of chemotherapy, targeted therapy, immunotherapy, and radiation therapy to help optimize quality of life and prolong survival in this vulnerable patient population. Includes chapters on how cancer therapy affects the myocardium, valves, pericardium and cardiac electrical system including handy reference tables on typical side effects of commonly used cancer therapies. Provides practical guidance in an easy-to-follow format that covers definition, associated drugs/therapies, epidemiology, diagnosis (history, physical exam, and diagnostic testing), treatment, and outcome/prognosis. Covers the role of non-invasive imaging modalities in the diagnosis and screening for cardiovascular disease including echocardiography, MRI, and nuclear imaging. Addresses frequently encountered clinical scenarios such as preoperative or pre-high-risk treatment evaluation with up-to-date expert consensus recommendations. Details emerging treatments and optimal use of non-invasive imaging in cardiac amyloidosis. Features easy-to-use flow-charts and tables that aid in the differentiation of cardiac masses. The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by Wolters Kluwer Health under license from Washington University. Enrich Your eBook Reading Experience Read directly on your preferred device(s),such as computer, tablet, or smartphone. Easily convert to audiobook,powering your content with natural language text-to-speech.

Read more less

Book Synopsis

Read more less

Book SynopsisThis groundbreaking book presents a unique and practical approach to the evolving field of exercise oncology - the study of physical activity in the context of cancer prevention and control. Presenting the current state of the art, the book is sensibly divided into four thematic sections. Following an opening chapter presenting an overview and timeline of exercise oncology, the chapters comprising part I discuss primary cancer prevention, physical activity and survivorship, and the mechanisms by which these operate. Diagnosis and treatment considerations are discussed in part II, including prehabilitation, exercise during surgical recovery, infusion and radiation therapies, and treatment efficacy. Post-treatment and end-of-life care are covered in part III, including cardio-oncology, energetics and palliative care. Part IV presents behavioral, logistical and policy-making considerations, highlighting a multidisciplinary approach to exercise oncology as well as practical matters such as reimbursement and economics.Written and edited by experts in the field, Exercise Oncology will be a go-to practical resource for sports medicine clinicians, family and primary care physicians, oncologists, physical therapy and rehabilitation specialists, and all medical professionals who treat cancer patients.Table of ContentsChapter 1. Exercise Oncology: Past and Present Kathryn H. SchmitzPart 1 - Physical Activity and Cancer Prevention Chapter 2. Primary PreventionErika Rees-Punia, Alpa V. Patel Chapter 3. Physical Activity and Cancer SurvivalChristine M. Friedenreich, Chelsea R. Stone, Sandra C. Hayes Chapter 4. Mechanisms of Exercise in Cancer Prevention, Treatment and SurvivorshipHannah Savage, Keri L. Schadler Part 2 - From Diagnosis through TreatmentChapter 5. Exercise Oncology from Diagnosis through Treatment: An Overview of Outcomes and ConsiderationsCiaran M. Fairman, Daniel A. GalvãoChapter 6. Prehabilitation: An Emerging Standard in Exercise OncologyNicole L. Stout, Julie K Silver, Jennifer Baima, Sasha E. Knowlton, Xiaorong HuChapter 7. Exercise during Surgical Recovery Rosa M. Pasculli, Jonas Sokolof, Elizabeth Olecki, Kelly Stahl, Niraj GusaniChapter 8. Exercise during Infusion TherapyKristin L. Campbell, Amy KirkhamChapter 9. Exercise During Radiation TherapyJoachim WiskemannChapter 10. Effects of Exercise on Cancer Treatment Completion and EfficacyAndria R. Morielli, Kerry S. Courneya Part 3 – Post-treatment to End of LifeChapter 11. Exercise Oncology from Post-Treatment to End of Life: An Overview of Outcomes and ConsiderationsKira Bloomquist, Sandra C. Hayes Chapter 12. Exercise during Immediate Post-treatment Kerri Winters-Stone, Mary Medysky, Anna L. SchwartzChapter 13. Long-term and Late Effects of Cancer Treatments on Prescribing Physical ActivityAnna L. Schwartz, Jennifer W. Bea, Kerri Winters-StoneChapter 14. Exercise and Cardio-OncologyAmy M. Berkman, Susan C. Gilchrist Chapter 15. Energetics and Cancer OutcomesLeah M. Ferrucci, Melinda L. IrwinChapter 16. Exercise for Advanced Cancers, Metastatic Disease and Palliative CareSonya Lowe, Christopher Sellar, Kirsten Suderman, Margaret L. McNeely Part 4 - Behavior, logistics, and policyChapter 17. Cancer Survivors Becoming and Staying Physically Active: Challenges of Behavior ChangeBernardine M. Pinto, Madison M. Kindred, Chloe GrimmettChapter 18. Making Exercise Standard in Cancer Care Karen Basen-Engquist, Nathan H. ParkerChapter 19. Viewing Exercise Oncology through the Lens of MultidisciplinarityMartijn M. StuiverChapter 20. Policy and Reimbursement Considerations for Exercise Programming in CancerAndrea Cheville, Jennifer Baima, Philip Chang, Charles Mitchell, Stephanie Otto, Sonal Oza, David S. ZuckerChapter 21. Shaping the Future of Exercise OncologyKathryn H. Schmitz

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis book provides a thorough background to the emerging field of medical robotics. It covers the mathematics needed to understand the use of robotic devices in medicine, including but not limited to robot kinematics, hand-eye and robot-world calibration, reconstruction, registration, motion planning, motion prediction, motion correlation, motion replication and motion learning. Additionally, basic methods behind state-of-the art robots like the DaVinci system, the CyberKnife, motorized C-arms and operating microscopes as well as stereotactic frames are presented. The book is a text book for undergraduates in computer science and engineering.The main idea of the book is to motivate the methods in robotics in medical applications rather than industrial applications. The book then follows the standard path for a robotics textbook. It is thus suitable for a first course in robotics for undergraduates. It is the first textbook on medical robotics.Table of ContentsIntroduction.- Describing Spatial Position and Orientation.- Robot Kinematics.- Joint Velocities and Jacobi-Matrices.- Navigation and Registration.- Treatment Planning.- Motion Correlation and Tracking.- Motion Prediction.- Motion Replication.- Applications of Surgical Robotics.- Rehabilitation, Neuroprosthetics and Brain-Machine Interfaces.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis richly illustrated book provides a comprehensive survey of the growing role of medical imaging studies in the detection, staging, grading, tissue characterization, and post-treatment follow-up of soft tissue tumors. For each tumor group, imaging findings are correlated with clinical, epidemiologic, and histologic data. The relative merits and indications of various imaging modalities are discussed and compared. Particular emphasis is placed on MRI because of its unique contrast resolution and multiplanar imaging capabilities. This third, revised and updated edition includes new chapters on genetics and molecular biology and on pathology of soft tissue tumors, with respect to the new World Health Organization (WHO) classification of soft tissue tumors. It aims to serve both as a systematic, descriptive textbook and as a rich pictorial database of soft tissue masses. The addition of numerous new illustrations of common and rare soft tissue tumors will further increase the scientific and educational value of this third edition.Trade ReviewFrom the reviews of the third edition: RAD-Magazine, Nov. 2006: "There is a lot of knowledge and experience between the two book covers, which is well presented...." "This third edition of ‘Imaging of soft tissue tumors’ has been considerably enlarged by using the bank data of the Belgian Soft Tissue Neoplasm Registry. … This new edition should be recommended to radiologists and nuclear medicine doctors, surgeons, oncologists, graduated or in training, but it is also of interest for the specialists related to the different soft tissues." (F Duparc, Surgical and Radiologic Anatomy, Vol. 28, 2006)Table of ContentsDiagnostic Modalities.- Ultrasound of Soft Tissue Tumors.- Color Doppler Ultrasound.- Plain Radiography, Angiography, and Computed Tomography.- Nuclear Medicine Imaging.- Magnetic Resonance Imaging.- Dynamic Contrast-Enhanced Magnetic Resonance Imaging.- Cytogenetics and Molecular Genetics of Soft Tissue Tumors and Bone Tumors.- Soft Tissue Tumours: the Surgical Pathologist’s Perspective.- Biopsy of Soft Tissue Tumors.- Staging, Grading, and Tissue Specific Diagnosis.- Staging.- Grading and Tissue-Specific Diagnosis.- General Imaging Strategy of Soft Tissue Tumors.- Imaging of Soft Tissue Tumors.- Tumors of Connective Tissue.- Fibrohistiocytic Tumors.- Lipomatous Tumors.- Tumors and Tumor-like Lesions of Blood Vessels.- Lymphatic Tumors.- Tumors of Muscular Origin.- Synovial Tumors.- Tumors of Peripheral Nerves.- Extraskeletal Cartilaginous and Osseous Tumors.- Primitive Neuroectodermal Tumors and Related Lesions.- Lesions of Uncertain Differentiation.- Pseudotumoral Lesions.- Soft Tissue Metastasis.- Soft Tissue Lymphoma.- Imaging of Soft Tissue Tumors in The Pediatric Patient.- Imaging After Treatment.- Follow-Up Imaging of Soft Tissue Tumors.

Read more less

Book SynopsisWritten by internationally renowned experts, Clinical Ophthalmic Oncology provides practical guidance and advice on the diagnosis and management of the complete range of ocular cancers. The book supplies all of the state-of-the-art knowledge required in order to identify these cancers early and to treat them as effectively as possible. Using the information provided, readers will be able to provide effective patient care using the latest knowledge on all aspects of ophthalmic oncology, to verify diagnostic conclusions based on comparison with numerous full-color clinical photographs, and to locate required information quickly owing to the clinically focused and user-friendly format. This volume describes the classification, differential diagnosis, and imaging of orbital tumors and discusses the most suitable treatment options for different tumor types.​Trade Review“The volume covers all steps of the treatment process, from diagnostics reflections through surgical techniques and rehabilitation of the patient at the end of the medical treatment itself. The book consists of 19 chapters beginning with examination techniques and classification of orbital tumors. … The large number of clinical and histological images is of very high quality. … the second edition of ‘Orbital Tumors’ by Perry and Singh is a ‘must-read’ for all ophthalmologists treating patients with orbital diseases.” (Eckart Bertelmann, Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 254, 2016)Table of ContentsExamination Techniques.- Classification of Orbital Tumors.- Differential Diagnosis in Child.- Differential Diagnosis in Adults.- Imaging Techniques.- Non-Specific Orbital Inflammation.- Orbital Vascular Tumors.- Benign Orbital Tumors.- Optic Nerve Tumors.- Lacrimal Gland Tumors.- Lacrimal Sac Tumors.- Orbital and Adnexal Lymphoma.- Malignant Orbital Tumors.- Orbital Rhabdomyosarcoma.- Enucleation for Ocular Tumors.- Orbital Exenteration.- Principles of Orbital Surgery.- Orbital Implants.- Ocular Prosthesis.​

Read more less

Book SynopsisIn this volume an account is given of the technologies relevant to the detection of sentinel lymph nodes in the context of surgical oncology. This is a rapidly and evolving field, and the clinical applications discussed in this volume are exciting and important. A multidisciplinary team was assembled to discuss this subject in the light of direct experience gained by each of the groups in the previous 12 months. Clinical case material is presented and the methodology of sentinel lymph node imaging and detection is discussed in detail. The authors have assembled in a single volume a significant amount of personal data and a comprehensive literature review which will serve as a single reference and teaching source for all those interested in this critical technique relevant to the management of large numbers of patients in surgical oncology.Trade Review"...an excellent overview of a rather fashionable topic ...very didactic, with a wealth of colour pictures illustrating techniques, anatomy, histology and imaging procedures ...the contents are highly up-to-date and accurately report the data available today. I would recommend it to all surgeons, oncologists. histopathologists and nuclear medicine physicians." European Journal of Nuclear MedicineTable of Contents1. Sentinel Node Detection and Imaging 2. Radiopharmaceuticals 3. Radiation Detectors 4. How to choose a probe 5. Injection Techniques 6. Imaging Techniques 7. Surgical Techniques 8. Dosimetry and Radioation Protection 9. Histopathology of the Sentinel Node 10. Cytology of the Sentinel Node 11. Clinical Case Material 12. Malignant Melanoma: European Practice 13. Preliminary Study of Cost 14. The Future Subject index

Read more less

Book SynopsisCarcinogenesis.- Inhalation Carcinogenesis: An Overview.- Lung Carcinogenesis During in Vivo Cigarette Smoking and Radon Daughter Exposure in Rats.- Epithelial Lesions Induced by Alpha Particles and Cigarette Smoke Condensates in Organotypic Culture of Human Bronchus.- Asbestos Carcinogenesis: Asbestos Interactions and Epithelial Lesions in Cultured Human Tracheobronchial Tissues and Cells.- Histogenesis.- The Contribution of Uranium Miners to Lung Cancer Histogenesis.- Pathogenesis of Bronchial Carcinoma, with Special Reference to Morphogenesis and the Influence on the Bronchial Mucosa of 20-Methylcholanthrene and Cigarette Smoking.- Lung Cancer Histogenesis Following in Vivo Bronchial Injections of 20-Methylcholanthrene in Dogs.- Localization of Occult Lung Cancer.- Bronchoscopie Localization of Radiologically Occult Cancer.- Hematoporphyrin Derivative as a Tumor Marker in the Detection and Localization of Pulmonary Malignancy.- Fluorescence Bronchoscopy for Localizing Early Bronchial Cancer and Carcinoma in Situ.- Fluorescence Fiberoptic Bronchoscopy in the Diagnosis of Early Stage Lung Cancer.- Results of Early Lung Cancer Detection Programs.- Results of a Lung Cancer Detection Program in an Asbestos Industry.- Lung Cancer Mortality in Males Screened by Chest X-ray and Cytologic Sputum Examination: A Preliminary Report.- Sputum Cytology and Asbestos Exposure: A Preliminary Report.- Lung Cancer Screening Programs in Canadian Uranium Mines.- Detection of Early and Roentgenologically Occult Bronchogenic Carcinoma: Preliminary Report of the Sabbatsberg Hospital Sputum Cytologic Screening Study.- Results of Lung Cancer Screening Programs in Japan.- Results of the Memorial Sloan-Kettering Lung Project.- Results of the Mayo Lung Project: An Interim Report.Table of ContentsCarcinogenesis.- Inhalation Carcinogenesis: An Overview.- Lung Carcinogenesis During in Vivo Cigarette Smoking and Radon Daughter Exposure in Rats.- Epithelial Lesions Induced by Alpha Particles and Cigarette Smoke Condensates in Organotypic Culture of Human Bronchus.- Asbestos Carcinogenesis: Asbestos Interactions and Epithelial Lesions in Cultured Human Tracheobronchial Tissues and Cells.- Histogenesis.- The Contribution of Uranium Miners to Lung Cancer Histogenesis.- Pathogenesis of Bronchial Carcinoma, with Special Reference to Morphogenesis and the Influence on the Bronchial Mucosa of 20-Methylcholanthrene and Cigarette Smoking.- Lung Cancer Histogenesis Following in Vivo Bronchial Injections of 20-Methylcholanthrene in Dogs.- Localization of Occult Lung Cancer.- Bronchoscopie Localization of Radiologically Occult Cancer.- Hematoporphyrin Derivative as a Tumor Marker in the Detection and Localization of Pulmonary Malignancy.- Fluorescence Bronchoscopy for Localizing Early Bronchial Cancer and Carcinoma in Situ.- Fluorescence Fiberoptic Bronchoscopy in the Diagnosis of Early Stage Lung Cancer.- Results of Early Lung Cancer Detection Programs.- Results of a Lung Cancer Detection Program in an Asbestos Industry.- Lung Cancer Mortality in Males Screened by Chest X-ray and Cytologic Sputum Examination: A Preliminary Report.- Sputum Cytology and Asbestos Exposure: A Preliminary Report.- Lung Cancer Screening Programs in Canadian Uranium Mines.- Detection of Early and Roentgenologically Occult Bronchogenic Carcinoma: Preliminary Report of the Sabbatsberg Hospital Sputum Cytologic Screening Study.- Results of Lung Cancer Screening Programs in Japan.- Results of the Memorial Sloan-Kettering Lung Project.- Results of the Mayo Lung Project: An Interim Report.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisIn the past 10 to IS years there has been dramatic improvement in the survival of children with acute lymphoblastic leukemia. At the present time, over 50% of children with this disease will be alive and free of their disease at least 5 years from the time of their initial diagnosis. Although a number of factors have contributed to this improvement, perhaps none has been as important as the institution of central nervous system preventive therapy (eNS prophylaxis). However, despite the efficacy of eNS prophylaxis, the prevention and treatment of central nervous system leukemia continues to pose a formidable clinical challenge to the pediatric oncologist. Although successful in most cases, eNS preventive therapy remains ineffective for a small but significant subset of patients at high risk for developing eNS disease. Moreover, it has become increasingly evident that some methods of eNS preventive therapy are associated with long-term, adverse eNS sequelae. Thus, considerable controversy exists regarding the optimal method of eNS prophylaxis. Treatment of the patient who develops overt meningeal leukemia has not been as successful and continues to pose a major clinical challenge. Despite the ability of intrathecal chemotherapy and/or radiation therapy to induce eNS remission, most patients suffer subsequent relapse and ultimate survival is usually signifi­ cantly compromised. It is evident that newer approaches to treatment for this patient group must be identified before major improvement for this patient group is likely to occur.Table of Contents1. The Pathology of Central Nervous System Leukemia.- 2. Radiation Therapy Methods for Central Nervous System ‘Prophylaxis’ in the Management of Childhood Leukemias.- 3. Central Nervous System Prophylaxis for Therapy of Acute Lymphocytic Leukemia.- 4. Reduction in Central Nervous System Leukemia with a Pharmaco-kinetically derived Intrathecal-Methotrexate Dosage Regimen.- 5. Central Nervous System Prophylaxis with Intermittent Intrathecal Methotrexate and Fractional Radiation in Childhood Acute Lymphoblastic Leukemia.- 6. Intermittent Intrathecal Methotrexate and Fractional Radiation plus Chemotherapy in Childhood Lymphoblastic Leukemia.- 7. Prophylaxis of Central Nervous System Leukaemia: British Experience, 1970–80.- 8. The Norwegian Methotrexate Study in Childhood Acute Lymphocytic Leukemia.- 9. Therapy Related Central Nervous System Diseases in Children with Acute Lymphocytic Leukemia.- 10. Neurotoxic Complications of CNS Prophylaxis in Childhood Leukaemia.- 11. Evaluation of Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia.- 12. Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia.- 13. Treatment of Overt CNS Leukaemia.- 14. Radiation Therapy Methods for the Treatment of Central Nervous System Leukemia.- 15. Treatment of Meningeal Leukemia: Investigation of New Approaches with Conventional Agents.

Read more less

Book SynopsisMagnetic resonance imaging has already become a most valuable imaging modality in the diagnostic work-up of musculoskeletal neoplasms. While high accuracy of MRI for staging purposes has been proven, we will focus in this monograph on the characterization of primary bone and soft tissue tumors by MRI. The major purpose of this monograph is to provide an atlas of magnetic resonance features of primary bone and soft tissue tumors for radiologists, orthopedic surgeons and physiotherapists. The results presented are based on investigations of 94 primary bone and soft tissue tumors and mimicking conditions by magnetic resonance imaging. Although the scale of the material allows for statistical handling, the number of patients per subgroup is too small to come to definite conclusions. We will therefore limit ourselves to the description of and comments on a great number of cases to illustrate the diagnostic potential of this new imaging modality. We would like to thank the anonymous cooperators: referring clinicians, pathologists, nurses, technicians and secretaries whose help enabled us to present this monograph. We would also like to express our gratitude to the firms Siemens AG and Schering AG for technical support.Table of Contents1 General Considerations about Bone and Soft Tissue Tumors.- 2 Materials and Methods.- Benign Bone Tumors and Mimicking Conditions.- 3 Osteoid Osteoma.- 4 Enchondroma.- 5 Osteochondroma.- 6 Giant Cell Tumor.- 7 Vertebral Hemangioma.- 8 Solitary Bone Cyst.- 9 Aneurysmal Bone Cyst.- 10 Non Ossifying Fibroma.- 11 Eosinophilic Granuloma.- 12 Fibrous Dysplasia.- 13 Osteomyelitis.- Malignant Bone Tumors.- 14 Osteogenic Sarcoma.- 15 Chondrosarcoma.- Benign Soft Tissue Tumors.- 16 Lipoma.- Neurogenic Tumor.- Soft Tissue Hemangioma.- Aggressive Fibromatosis.- Malignant Soft Tissue Tumors.- 17 Liposarcoma.- 18 Malignant Fibrous Histiocytoma.- 19 Rhabdomyosarcoma.- 20 Value of Contrast (Gd-DTPA)-Enhanced MRI Studies in Cases of Musculoskeletal Tumors.- 21 General Conclusions.

Read more less

Book SynopsisDespite the fact that the incidence of gastric cancer is declining in the Western world, it remains a significant problem with respect to accurate diagnosis and treatment since it has a high mortality rate. In June 1989 an International Conference was held at the University of Rome "La Sapienza" entitled "New Trends in Gastric Cancer: Background and videosurgery". During this meeting background information on the aetiopathogenesis of gastric cancer was presented together with talks and video presentations on the latest advances in the treatment of gastric carcinoma, both from the European and Japanese experience. Because of the poor prognosis of gastric carcinoma there is increasing pressure for early detection. Some of the problems in the early detection of gastric carcinoma are discussed together with methods of surveillance of high-risk subjects. It is generally accepted that the surgical approach to gastric carcinoma should take into account the site and extent of the lesion and there are chapters on new methods for pre and intraoperative staging of the disease which allow a more logical approach to surgery. A comparison between Japanese and Western rule and results was attempted and reasons for the differences were investigated. Since the field is still evolving not all aspects could be covered, and those angles not approached in this book will be addressed in a second International Conference to be held in Rome in June 1990.Table of ContentsSection 1 Background.- 1 Epidemiology and machanism of gastric carcinogenesis.- 2 Histiogenesis and precursors of human gastric cancer.- 3 N-nitroso compounds, gastric carcinogenesis and chemoprevention.- 4 Analytical problems in the determination of N-nitroso compounds in gastric juice.- 5 Early detection of patients at high risk of developing gastric cancer.- 6 Prospects for early detection of gastric cancer and precancerous lesions.- Section 2 New Trends in Diagnosis.- 7 New trends in electronic videoendoscopy of the digestive tract.- 8 Endosonography: its diagnostic utilities for gastric cancer.- 9 Flow cytometry in gastric cancer.- Section 3 Surgical Treatment of Gastric Cancer.- 10 Intraoperative staging in gastric cancer surgery.- 11 New technologies in gastric cancer surgery: Computer system to make operation plan and intraoperative staining of regional lymph nodes for complete dissection.- 12 The general rule of the Japanese Research Society for Gastric Cancer and treatment results by the rule.- 13 A European multicentre retrospective study in cancer of stomach.- 14 Surgical treatment of gastric cancer: our elective procedures for desirable curability.- 15 “Regional” gastrectomy.- 16 Total gastrectomy in the surgical treatment of gastric cancer.- 17 The role of extensive surgery in advanced gastric cancer.- 18 The importance of extended lymphadenectomy in gastric cancer surgery.- 19 Duodenopancreatectomy for gastric cancer.- 20 Reconstruction after total gastectomy.

Read more less

Book SynopsisRelapse of leukemia following successful remission-induction therapy remains a major obstacle in the treatment of patients with acute leukemia. Leukemia recurs most frequently in patients with acute myeloblastic leukemia (AML) and high risk acute lymphoblastic leukemia (ALL) following chemotherapy and less often in patients with low risk ALL and particularly in patient groups> submitted to allogeneic marrow transplantation. ' It is likely that the great majority of these recurrences originate from residual leukemic cells that survive initial remission-induction chemotherapy. Today, several research groups throughout the world place emphasis on studies concerned with the detection and treatment of 'minimal residual disease' (MRD). These investigations are conducted with the common objective to tackle the remaining cells. 'Minimal Residual Disease in Acute Leukemia: 1986' summarizes the fast advancements in this area. Several disciplines are concerned with the analysis of leukemic cells. The perspectives of cytogenetic and molecular genetic approaches for applica­ tion in the detection of MRD are reviewed. In this respect, modern cyto­ genetics provide highly specific tumor markers. The resolution of cyto­ genetic methods can be particularly improved when combined with other techniques which select relevant subpopulations of cells. Characterization of oncogenes and gene rearrangements, including those of immunoglobulin and T-cell receptor genes, and the measurement of gene products, have been established. Techniques based on these approaches offer interesting tools for the detection of MRD. New possibilities of employing monoclonal anti­ bodies are also presented.Table of ContentsI — Detection of Minimal Residual Disease in Acute Leukemia.- New possibilities for cytogenetic analysis of leukemic cells.- Breakpoint analysis in CML: potentials for detection of minimal residual disease.- The mammalian ETS genes: two unique chromosomal locations in cat, mice and man and novel translocated position in human leukemias.- Activated RAS oncogenes in acute leukemia.- DNA rearrangements as unique markers of clonal evolution, recurrence and translocation.- The application of monoclonal antibodies for the detection and classification of AML.- Towards detection of minimal disease: discrimination of AML precursors from normal myeloid precursors using a combination of surface makers.- An immunological approach to analyse the kinetics of minimal residual disease in acute leukemia.- Visualization of minor cell populations with simultaneous three-parameter flow cytometry: BN rat marrow and spleen model.- Growth kinetics of minimal residual disease in the brown Norway rat acute myelocytic leukemia.- Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: possibilities and limitations.- Surveillance of terminal deoxynucleotidyl transferase-positive cells in peripheral blood of patients with acute lymphoblastic leukemia.- In vitro colony forming cells of acute lymphoblastic leukemia: analysis of 24 cases with recombinant interleukin 2 as growth stimulus.- II — Intensive Chemotherapy Regimens for ‘Minimal Residual Disease’ in Acute Myeloblastic and Lymphoblastic Leukemia.- Biologic and treatment determinants of curability in acute myologenous leukemia.- High-dose cytosine-arabinoside plus AMSA for reinduction or consolidation-maintenance in acute myelogenous leukemia.- Treatment of residual disease in AML: interim analysis of a southeastern cancer study group prospective randomized clinical trial.- L-20 protocol for adult patients with acute lymphoblastic leukemia: a protocol utilizing prognostic factors, intensive chemotherapy and autologus “purged” marrow transplantation to eradicate minimal residual disease.- Treatment of minimal residual disease in adult ALL: the German national study.- Treatment of minimal residual disease in “poor risk” acute lymphoblastic leukaemia with high-dose cytosine arabinoside.- III Autologous Bone Marrow Transplantation for the Eradication of ‘Minimal Residual Leukemia’.- Autologous bone marrow transplantation in first remission AML using non-purged marrow — update.- Double autografting: a potential curative regimen for acute leukaemia?.- Autologous bone marrow transplantation in acute nonlymphocytic leukemia. A study of ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.- Attempts to eliminate residual acute myeloid leukemia from autologous bone marrow grafts through in vitro chemotherapy — a review.- Monoclonal antibody purged autologous bone marrow transplantation for relapsed non T-cell acute lymphoblastic leukemia.- Allogeneic and autologous marrow transplantation: ex vivo purging with monoclonal antibody or immunotoxins to remove leukemic cells or to prevent graft versus host disease.- Detection and selective destruction of tumor cells by the lipophilic dye, merocyanine 540.- IV Allogeneic Bone Marrow Transplantation for the Eradication of ‘Minimal Residual Leukemia’.- Factors influencing long-term leukemia-free survival after allogeneic bone marrow transplantation for acute leukemia.- Bone marrow transplantation with HLA identical donors in the acute leukemias — Baltimore experience.- Results of allogeneic marrow transplantaton in patients transplanted for acute leukemia: a long-term follow-up.- Bone marrow transplantation in first CR of acute leukaemia using T-depleted marrow from HLA identical sibling donors.- Soybean lectin agglutination and E-rosette depletion for removal of T-cells from HLA-identical marrow grafts: results in 60 consecutive patients transplanted for hematologic malignancy.- Allogeneic bone marrow transplantation in adult leukemia: result of T-cell depletion by soybean lectin fractionation.- Rapid lymphocyte depletion by a new elutriator rotor for the prevention of acute graft versus host disease after allogeneic bone marrow transplantation.- Problems and prospect of histoincompatible bone marrow transplantation studied in rhesus monkeys.- Allogeneic marrow transplantation for the treatment of leukemia. Role of the major histocompatibility complex.- Summing up.- Minimal residual disease in leukemia: 1986.- Index of subjects.

Read more less

Book SynopsisThe objective of the treatment of acute leukemia involves the eradication of all neoplastic cells, including the last one. Ideally, treatment should be controlled by monitoring cell kill. If the last cells could be discovered and their biological properties be determined, the qualitative and quantitative effects of treatment should be directly evaluable. This should ultimately permit a calculated tumor cell reduction thereby avoiding overtreatment and excessive toxicity and thus providing a basis for individualized antileukemic treatment. In recent years several new developments have contributed to the selective discovery of minimal numbers of leukemic cells which are hidden among the normal cells in the marrow cavities. These methods are the first steps to the realization of the therapeutic goals indicated above. They include the production and ap­ plication of monoclonal antibodies against differentiation antigens on the cell sur­ face, the use of pulse cytophotometry - and cell sorter techniques, the employment of cytogenetics, the development of culture techniques for selective growth of precursor cells and several others. These methodologies offer prospects for refined diagnosis and, as far as the elimination of leukemic cells is concerned, the further development of autologous bone marrow transplantation. Eliminating tumor cells from autologous grafts requires the detailed knowledge of the cellular inter­ relationships within the neoplasm so that the neoplastic cells responsible for tumor propagation are specifically removed. Recognition and characterization of the clonogenic cells of the neoplasm should then lead to determining their sensitivity to the therapeutic agents which are clinically applied.

Read more less

Book SynopsisThe Third Breast Cancer Working Conference of the Breast Cancer Cooperative Group of the European Organization for Research on Treatment of Cancer, to be held in Amsterdam on April 27-29, 1983, was the principle motive for writing this book. It was feh that a short review of the main pathogenetic conceptions and therapeutic principles which have presented themselves with regard to mammary cancer in the Course of Western history , might help to draw a more complete picture of where we stand today. It is not easy to decide which ideas, although discarded, deserve yet to be remembered and which authors from the past may be considered to be truly representative of the scientific climate of their age. Twenty centuries have produced quite a lot of ideas and the number of medical authors who advanced, or rejected, or modified, or revived them, is really uncountable. So the historian has to make a selec­ tion and choices are perforce subjective and open to criticism. In writing this book I tried to consult original sources in the original language as much as possible. These sources were not always strictly medical since I aimed at placing the problem of malignant breast disease - which might serve as a paradigm of cancer in general - in a somewhat wider context. For the history of medicine is not only a history of ideas, but also that of people, of institutions, of society.Table of Contents1. Antiquity.- 2. The Middle Ages.- 3. The Renaissance.- 4. Pathophysiological concepts in the Age of Enlightenment.- 5. Diagnosis and therapy in the eighteenth century.- 6. Europe during Napoleon and after.- 7. Scientific developments in the second half of the nineteenth century.- 8. Mammary carcinoma in the light of new developments.- 9. Surgical treatment in the second half of the nineteenth century.- 10. The twentieth century.- Epilogue.- Notes.- Index of names.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis exciting reader-friendly book addresses the general perspectives of cancer in diverse ways — everyday lifestyle, nutrition, environmental factors as well as genetics. The author, an expert in Immuno-Oncology, makes conscious efforts to break down the complexities of cancer development through the use of scientific evidences and everyday activities. There are so many myths about cancer out there. This book employs scientific basis to separate the facts from the myths while making it comprehensible to all readers irrespective of their scientific background. Readers are also introduced to the modern trends in cancer therapeutics.

Read more less

Book SynopsisThis eighteenth volume of the Evidence-based Clinical Chinese Medicine series aims to provide a multi-faceted 'whole evidence' analysis of the management of pain due to a range of cancers (cancer pain) using integrative Chinese medicine.Beginning with an overview of how cancer pain is conceptualised and managed in conventional medicine, the authors then summarise the differential diagnosis and managment of cancer pain in contemporary Chinese medicine based on clinical guidelines and contemporary books. The third chapter provides detailed analyses of how cancer pain and related disorders were treated with herbal medicine and acupuncture in past eras based on the classical Chinese medical literature.The subsequent chapters comprehensively review the current state of the clinical trial evidence for the integrative application of Chinese herbal medicines (Chapter 5), acupuncture (Chapter 7), other Chinese medicine therapies (Chapter 8) and combination Chinese medicine therapies (Chapter 9) in the management of cancer pain, as well as analyse and evaluate the results of these studies from an evidence-based medicine perspective. Chapter 6 reviews and summarises experimental evidence for the bioactivity of commonly used Chinese herbs and their constituent compounds. The outcomes of these analyses are summarised and discussed in Chapter 10 which alsoidentifies implications for the clinical practice of Chinese medicine and for future research.This book can inform clinicians and students in the fields of integrative medicine and Chinese medicine regarding contemporary practice and the current evidence base for a range of Chinese medicine therapies used in the management of cancer pain, including herbal formulas and acupuncture treatments, in order to assist clinicians in making evidence-based decisions in patient care. It also provides researchers with a comprehensive summary of the state of the field than can inform future.The following features mark the importance of this book in the field:Table of ContentsEvidence-Based Chinese Medicine; Classical Chinese Medicine Literature for Cancer Pain and Associated Disorders; Contemporary Clinical Management of Cancer Pain with Integrative Chinese Medicine; Assessment of the Clinical Trial Evidence for Chinese Herbal Medicine, Acupuncture Therapies, Remedial Massage, and Combinations of Chinese Medicine Therapies in Integrative Cancer Pain Management;

Read more less

Book SynopsisThis book offers essential information on basic and translational research in gastric cancer, while also illustrating potential opportunities for its application in clinical practice. Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths. It is known to be a heterogeneous disease with varied responses to “one-size-fits-all” treatments. Expanding our knowledge of cancer cell genetics may help us to explore more effective treatments in gastric cancer. The research on molecular mechanisms and its clinical applications, both presented here, will help readers gain an in-depth understanding of gastric cancer and its effective treatment.The book’s four sections cover personalized medicine, precise regional therapy, immunotherapy and nanomedicine in gastric cancer. Each part presents the state of art, recent advances and the authors’ experiences. Moreover, several interesting cases are described to demonstrate how gastric cancer patients benefit from translational research. This informative and attractively presented book on precision treatment in gastric cancer, including experimental findings and clinical treatment options, offers a valuable resource for oncologists and graduate students working in the field of gastric cancer.Table of ContentsMolecular pathology of hereditary gastric cancer.- Genetics and molecular signature of gastric cancer.- Circulating tumor cells in gastric cancer.- Customized chemotherapy in advanced gastric cancer.- Targeted therapy in advanced gastric cancer.- Laparoscopic surgery and robotic surgery.- Radiotherapy in peritoneal metastatic gastric cancer.- Personalized intraperitoneal strategy in gastric cancer.- Checkpoint blockade therapy of gastric cancer.- Adoptive cell therapy of gastric cancer.- Combinational immunotherapy of gastric cancer.- Use of Nanomedicine in the diagnosis of gastric cancer.- Systemic drug delivery.- Local drug delivery.- Drug delivery in synergistic combination with other treatments.

Read more less

Book SynopsisThis book covers the discovery of molecular biomarkers, the development of laboratory testing techniques and their clinical applications, focusing on basic research to clinical practice. It introduces new and crucial knowledge and ethics of clinical molecular diagnosis. This book emphasizes the applications of clinical molecular diagnostic test on health management, especially from different diseased organs. It lets readers to understand and realize precision healthcare.Table of ContentsPart I Principles of Clinical Molecular DiagnosticsChapter 1 Molecules of Diseases and Their Detection Methods Chapter 2 Assay Performance Evaluation Chapter 3 Establishment of Biological Reference Interval Chapter 4 Ethics: Informed Consent, Patient Privacy Chapter 5 Bioinformatics Chapter 6 Report and Consultation Chapter 7 Factors Associated with Variation Chapter 8 Quality Control and Quality Assurance Chapter 9 Precision Medicine Part 2 Molecular Biomarkers and Signals from Diseased Functional Organ Chapter 10 Molecules in Body Systems Chapter 11 Molecules in Signal Pathways Chapter 12 Endocrine and Metabolism Chapter 13 Immune System Chapter 14 Lipoproteins Chapter 15 Transport and Carrier Proteins Chapter 16 Coagulation and Fibrinolysis Chapter 17 Cardiovascular System Chapter 18 Pregnancy Chapter 19 Urine Chapter 20 Bone Chapter 21 Cancer Chapter 22 Translation Research of Novel Biomarker Part 3 Advanced Molecular Diagnostic Techniques Chapter 23 Next-generation Sequencing (NGS) Chapter 24 Digital PCR Chapter 25 Biosensor Chapter 26 Microfluidic Chip Chapter 27 Liquid Biopsy Chapter 28 Molecular Targeted Imaging Chapter 29 Fluorescence in Situ Hybridization Chapter 30 Circulating DNA Quantification Chapter 31 DNA Methylation Detection Techniques Part 4 Disease Presentation and Clinical Laboratory Procedures Chapter 32 Immunological Disorders Chapter 33 Liver Diseases Chapter 34 Pancreatic Diseases Chapter 35 Digestive Tract Disease Chapter 36 Kidney Diseases Chapter 37 Cardiovascular Disease Chapter 38 Lung Disease Chapter 39 Blood Disorders Chapter 40 Endocrine and Metabolic Diseases Chapter 41 Neurological Disease Chapter 42 Reproductive Organ Cancer Chapter 43 Reproductive Organ Cancer Chapter 44 Transplant Matching Chapter 45 Paternity Test

Read more less

Book SynopsisThe main objective of this book is to present the recent applications of photodynamic therapy (PDT) in treating cancer and other diseases. The limitations associated with current PDT agents, and the synthetic designs that have been used in various laboratories are also discussed. The utility of certain tumor-avid agent for cancer imaging (fluorescence, PET, MRI) is also summarized. The book also includes the use of delivery vehicles, including nanoparticles in improving the tumor-specificity of the desired agents. The book is basically focused on the translational approach of drug development. By providing certain specific examples, a clear concept of moving a 'product' from the bench to bed-side is also discussed.To have a clear concept of drug development the book is divided in three parts — Medicinal Chemistry, Mechanistic and Clinical studies. Each part includes the contributions from the leading scientists with extensive experience in the respective field. The handbook is assembled by renowned scientists Dr Dougherty, known as the father of PDT, Dr Kessel, well known for his contributions on mechanism of PDT and Dr Pandey for his inventions in developing improved agents for PDT and cancer-imaging.Table of ContentsPart 1: Multifunctional Agents for Cancer-Imaging and Photodynamic Therapy: Monomers vs. Polyacrylamide-Based Nanoplatforms (Aimee Marko, Nayan J Patel, Penny Joshi, Joseph R Missert and Ravindra K Pandey); Design and Synthesis of Photosensitizers-peptide conjugates for PDT (Turslai M Williams, Martha Sibrian-Vazquez and M Graca H Vicente); Current Devcelopments in Using Meso (tetra) Substituted Porphyrins in PDT (Yasser M Shaker, Ayman M K Sweed, Claire Moylan, Luke Rogers, Aoife A Ryan, Rosine Petitdemange and Mathias O Senge); (Mike Detty et al.); Phthalocyanines in Cancer-Imaging and Therapy (Hasrat Ali and Johan E van Lier); Molecular Phthalocyanines-Based Photosensitizers for Photodynamic Therapy (Pui-Chi Lo, Sun Y S Chow and Dennis K P Ng); Porphyrin Nanoparticles for cancer Imaging and Photodynamic Therapy (Liyang Cui, Juan Chen and Gang Zheng); Photodynamic Therapy Dosimetry: A to Z (Michael S Patterson); Part 2: PDT: Death and Survival Pathways (David Kessel); Vascular Effect of Photodynamic Therapy of Tumors (Keith A Cengel, Charles B Simone and Theresa M Busch); ETNBS in Photodynamic Therapy (Nicholas H Nowell, Hsin-I Hung, Lauren A Austin and Conor L Evans); Negative Impact of Tumor-Generated Nitric Oxide on Photodtynamic Therapy (Albert W Girotti); On the use of Photodynamic Therapy, as Monotherapy or in Combination, in the Treatment of Polypoidal Choroidal Vasculopathy: an Update (Hubert van den bergh and Patrycja Nowak-Sliwinska); Part 3: Photodynamic Therapy of Head and Neck Cancer - What's Old and What's New (Merrill A Biel); Endoscopic Photodynamic Therapy for Advanced Inoperable Esophageal Cancer; PDT for Lung Cancer (Keishi Ohtani and Norihiko Ikeda); New Developments in Antimicrobial PDT (Wolfgang Baumler by Joerg Lindenmann);

Read more less

Book SynopsisThis book describes the use of stem cells and cancer stem cell generation in the inflammatory microenvironment (cancer-inducing niche) using induced pluripotent stem cells. It provides step-by-step techniques and manuals for studying stem cell and cancer stem cell generation with different applications in cancer research. The development of induced pluripotent stem cells has provided a new approach to studying cancer initiation by producing cancer stem cells without introducing mutations or foreign genes. The book features the research of the authors’ group, which was the first to generate cancer stem cells from stem cells in the presence of inflammatory conditions. The 20 chapters of this book cover topics such as generating pluripotent stem cells, converting normal stem cells to cancer stem cells, enriching, isolating and evaluating cancer stem cells. Methods for evaluating the characteristics of cancer stem cells and possible therapies against them are also discussed. The book provides easy-to-follow protocols that help researchers in the study of cancer stem cells. Illustrations help readers understand how the method of cancer stem cell generation can be applied as an essential method for assessing the carcinogenic potential of various non-mutagenic compounds. It will be a useful resource for graduate students, researchers, technicians, and physicians working in academic, hospital, and pharmaceutical settings. Table of Contents1. On the origin of cancer.- 2. Culture of Cells: Basic Principles .- 3. Stem cell culture from embryos.- 4. Reprogramming of normal cells.- 5. Maintenance of human Pluripotent Stem Cells.- 6. Identification of cancer stem cells by different molecular markers .- 7. Enrichment of Cancer Stem Cell from malignant tumor.- 8. Isolation of single clonal cell from primary cultured cells and establishment of a cancer stem cell line .- 9. Artificial Generation of Cancer Stem Cells from Normal Stem Cells.- 10. Quick method to assess non-mutagenic carcinogens with iPS cells.- 11. Self-renewal potential of caner stem cells.- 12. Differentiation potential of cancer stem cells in vitro.- 13. Tumor Angiogenesis by cancer stem cells in vivo.- 14. Invasion and Metastatic potential of cancer stem cells in vitro.- 15. Metastatic potential of cancer stem cells In Vivo- 16. Anchorage-independent cell growth assay for Cancer Stem Cells: Tumorigenic assay in vitro .- 17. Tumorigenic potential of cancer stem cells in vivo.- 18. Development of immunoliposomes using monoclonal antibodies targeting cancer stem cells .- 19. In-vitro evaluation of anti-cancer stem cell drugs .- 20. In vitro Tumoroid Model Using Cancer Stem Cells.

Read more less

Book SynopsisUnderstanding Lung Cancer, Second Edition, defines lung cancer and describes the two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Fully up to date with current guidelines, the chart describes how lung cancer is diagnosed and staged and lists risk factors, signs and symptoms, and treatment options. The main lung image shows the left upper lobe and left lower lobe with metastasis to paratracheal lymph nodes, metastasis to carinal lymph nodes, and a close-up, inset image of a tumor projecting into bronchi. The chart also describes how lung cancer can be prevented, includes a graphic showing how to calculate number of “pack years” along with an image of a cigarette in ashtray and the statistic that approximately 90 percent of lung cancer deaths are related to smoking. Featured sections: Risk Factors Signs and Symptoms Risk Factors Diagnosis and Staging Treatment Options How Can Lung Cancer Be Prevented? What’s a Pack Year? 20" x 26" heavy paper laminated with grommets at top corners

Read more less

Book SynopsisInsufficient supply of oxygen, i.e. hypoxia, typically occurs in a broad range of solid tumours due to aberrant vasculature. It is a key component of tumour microenvironment that affects many biological processes at molecular, cellular and tissue levels. Adaptive responses to oxygen deficiency shape signal transduction, cell metabolism, proliferation, differentiation, survival, angiogenesis, immunosurveillance etc. and thereby contribute to tumour invasion and metastasis. Presence of tumour hypoxia is significantly associated with poor prognosis and therapy resistance. Therefore, it represents a clinically relevant phenomenon that can be exploited for improvement of existing diagnostic and treatment procedures as well as for development of new targeted strategies. This book summarizes the current state of knowledge on hypoxia-regulated pathways and their biological consequences and describes promising approaches to clinical application of this knowledge. It is the first concise and complex guide to understanding principal basic and medical aspects of tumour hypoxia.Table of ContentsContents: Norma Masson/Peter J. Ratcliffe: Oxygen sensing by HIF hydroxylases – Thomas M.F. Connor/Patrick H. Maxwell: VHL inactivation – Carine Michiels: Oncogenic activation of HIF pathway – Katarzyna J. Nytko/Daniel P. Stiehl/Roland H. Wenger: PHD oxygen sensor function and antioxidants – Agnieszka Loboda/Halina Was/Urszula Florczyk/Alicja Jozkowicz/Jozef Dulak: Hypoxia-driven angiogenesis and other modes of blood vessel formation in tumours – Erik Olai Pettersen: Cell cycle alterations by hypoxic microenvironment – Eoin P. Cummins/Susan F. Fitzpatrick/Cormac T. Taylor: The role of NF-κB in hypoxia-induced gene expression – Roman Hrstka/Petr Müller/Philip J. Coates/Borivoj Vojtesek: Hypoxia and p53 – Thomas Kietzmann: Hypoxia: a powerful signal to induce metabolic changes – Eliska Svastova/Silvia Pastorekova: Hypoxia, regulation of pH and cell migration/invasion – Agnes Görlach: Reactive oxygen species and hypoxia signaling – Olga Krizanova: Calcium transport in hypoxia – Sandra Winning/Joachim Fandrey: HIF and inflammation – Martina Takacova/Tereza Goliasova/Juraj Kopacek: Hypoxia and oncogenic viruses – Sarah Peeters/Philippe Lambin/Ludwig Dubois: Noninvasive hypoxia imaging – Bart Reymen/Philippe Lambin: Hypoxia, hypoxia response and conventional anti-cancer therapy – Kaye J. Williams/Stephanie R. McKeown: Targeting hypoxic cells with bioreductive prodrugs – Annamaria Rapisarda/Nicole Fer/Giovanni Melillo: Targeting the hypoxic tumour microenvironment: a unique role for HIF-1 inhibitors – Claudiu T. Supuran: New drugs interfering with pH regulation in hypoxic tumours.

Read more less

Book SynopsisPart I: Development and cancer: basic concepts.- Chapter 1: Introductory chapter by Sorlie and Clarke.- Chapter 2: Embryonic mammary gland morphogenesis.- Chapter 3: Breast morphogenesis: from normal development to cancer.- Chapter 4: Single-Cell Analysis in the Mouse and Human Mammary Gland.- Part II: Development and cancer: model systems and approaches.- Chapter 5: Recording lineage history with cellular barcodes in the mammary epithelium and in breast cancer.- Chapter 6: Models for studying ductal carcinoma in situ progression.- Chapter 7: Patient-derived xenografts of breast cancer.- Chapter 8: Rat Models of Breast Cancer.- Part III: Development and cancer: cells of origin and heterogeneity.- Chapter 9: Cells of origin of breast cancer and intertumoral heterogeneity.- Chapter 10: Mechanisms of regulation of cell fate in breast development and cancer.- Chapter 11: Classification of breast cancer through the perspective of cell identity models.- Part IV:  Cellular and molecular basis.- Chapter 12: The Microenvironment in DCIS and its Role in Disease Progression.- Chapter 13: Molecular basis of breast tumor heterogeneity.- Chapter 14: E-cadherin-mediated cell-cell adhesion and invasive lobular breast cancer.- Part V: Signalling pathways.- Chapter 15: Hormone signaling in breast development and cancer.- Chapter 16: RANK/RANKL signaling pathway in breast development and cancer.- Chapter 17: Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis.- Part VI: Metastasis and immunity.- Chapter 18: Microenvironmental regulation of dormancy in breast cancer metastasis: An ally that changes allegiances.- Chapter 19: The Roles of Myeloid Cells in Breast Cancer Progression.- Chapter 20: Immune microenvironment in breast cancer metastasis.- Part VII:  Subtypes, treatment and resistance.- Chapter 21: Clinical Implications of Breast Cancer Intrinsic Subtypes.- Chapter 22: Targeting Estrogen Receptor signalling in breast cancer therapy.- Chapter 23: CDK4/6 inhibitor resistance in ER+ breast cancer.- Chapter 24: HER2-positive breast cancer treatment and resistance.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisPlease visit www.cancerstaging.org for information about content updates and staging forms.The AJCC Cancer Staging Manual is used by physicians and health care professionals throughout the world to facilitate the uniform description and reporting of neoplastic diseases. Proper classification and staging of cancer is essential for the physician to assign proper treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcome.Significantly expanded and developed by international disease site expert panels, the Eighth Edition AJCC Cancer Staging Manual brings together all the currently available knowledge on staging of cancer at various anatomic sites. In this edition, evidence-based TNM staging is supplemented, as appropriate, by selected molecular markers and newly acquired insights into the molecular underpinnings of cancer. This edition features 12 entirely new staging systems, a wide range of changed or new staging definitions, and a refined emphasis on a personalized-medicine approach. To enhance the print and electronic usability of the cancer staging forms, they are now available exclusively for access and downloading at www.cancerstaging.org.The Eighth Edition AJCC Cancer Staging Manual remains the gold standard reference for oncologists, surgeons, pathologists, radiologists, cancer registrars and medical professionals world-wide to ensure that all those caring for cancer patients are fully versed in the language of cancer staging.Trade Review“This is the most recent update of a manual for the staging of adult cancers from the American Joint Committee on Cancer. … This is a valuable reference for students, physicians, scientists, and cancer registrars. With clear descriptions and definitions of terminology, it can be used by experienced practitioners as well as those new to cancer staging. … Overall, this edition is a welcome update, incorporating new advances in cancer knowledge to more accurately reflect modern cancer care.” (Emily L. Albright, Doody's Book Reviews, February, 2017)Table of ContentsPart I General Information on Cancer Staging and End-Results Reporting.- 1. Principles of Cancer Staging.- . Organization of the AJCC Cancer Staging Manual.- 3. Cancer Survival Analysis.- 4. Risk Models for Individualized Prognosis in the Practice of Precision Oncology.- Part II Head and Neck.- 5. Staging Head and Neck Cancers.- 6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck.- 7. Lip and Oral Cavity.- 8. Major Salivary Glands.- 9. Nasopharynx.- 10. HPV-Mediated (p16+) Oropharyngeal Cancer.- 11. Oropharynx (p16−) and Hypopharynx.- 12. Nasal Cavity and Paranasal Sinuses.- 13. Larynx.- 14. Mucosal Melanoma of the Head and Neck.- 15. Cutaneous Squamous Cell Carcinoma of the Head and Neck.- Part III Upper Gastrointestinal Tract.- 16. Esophagus and Esophagogastric Junction.- 17. Stomach.- 18. Small Intestine.- Part IV Lower Gastrointestinal Tract.- 19. Appendix – Carcinoma.- 20. Colon and Rectum.- 21. Anus.- Part V Hepatobiliary System.- 22. Liver.- 23. Intrahepatic Bile Ducts.- 24. Gallbladder.- 25. Perihilar Bile Ducts.- 26. Distal Bile Duct.- 27. Ampulla of Vater.- 28. Pancreas – Exocrine.- Part VI Neuroendocrine Tumors.- 29. Neuroendocrine Tumors of the Stomach.- 30. Neuroendocrine Tumors of the Duodenum and Ampulla of Vater.- 31. Neuroendocrine Tumors of the Jejunum and Ileum.- 32. Neuroendocrine Tumors of the Appendix.- 33. Neuroendocrine Tumors of the Colon and Rectum.- 34. Neuroendocrine Tumors of the Pancreas.- Part VII Thorax.- 35. Thymus.- 36. Lung.- 37. Malignant Pleural Mesothelioma.- Part VIII.- Bone.- 38. Bone (appendicular skeleton, spine, and pelvis).- Part IX Soft Tissue Sarcoma.- 39. Introduction.- 40. Soft Tissue Sarcoma of the Head and Neck.- 41. Soft Tissue Sarcoma of the Trunk and Extremities.- 42. Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs.- 43. Gastrointestinal Stromal Tumor.- 44. Soft Tissue Sarcoma of the Retroperitoneum.- 45. Soft Tissue Sarcoma – Unusual Histologies and Sites.- Part X Skin.- 46. Merkel Cell Carcinoma.- 47. Melanoma of the Skin.- Part XI Breast.- 48. Breast.- Part XII Female Reproductive Organs.- 49. Introduction.- 50. Vulva.- 51. Vagina.- 52. Cervix Uteri.- 53. Corpus Uteri – Carcinoma and Carcinosarcoma.- 54. Corpus Uteri – Sarcoma.- 55. Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma.- 56. Gestational Trophoblastic Neoplasms.- Part XIII Male Genital Organs.- 57. Penis.- 58. Prostate.- 59. Testis.- Part XIV Urinary Tract.- 60. Kidney.- 61. Renal Pelvis and Ureter.- 62. Urinary Bladder.- 63. Urethra.- Part XV Ophthalmic Sites.- 64. Eyelid Carcinoma.- 65. Conjunctival Carcinoma.- 66. Conjunctival Melanoma.- 67. Uveal Melanoma.- 68. Retinoblastoma.- 69. Lacrimal Gland Carcinoma.- 70. Orbital Sarcoma.- 71. Ocular Adnexal Lymphoma.- Part XVI Central Nervous System.- 72. Brain and Spinal Cord.- Part XVII Endocrine System.- 73. Thyroid – Differentiated and Anaplastic Carcinoma.- 74. Thyroid – Medullary Carcinoma.- 75. Parathyroid.- 76. Adrenal Cortical Carcinoma.- 77. Adrenal – Neuroendocrine Tumors.- Part XVIII Hematologic Malignancies.- 78. Introduction.- 79. Hodgkin and Non-Hodgkin Lymphomas.- 80. Pediatric Hodgkin and Non-Hodgkin Lymphomas.- 81. Primary Cutaneous Lymphomas.- 82. Multiple Myeloma and Plasma Cell Disorders.- 83. Leukemia.- Part XIX Additional Contributors.- Index.

Read more less

Book SynopsisCompassionate, accessible, and informative, Understanding Cancer will increase the reader's knowledge of medical concepts and terms so the person with cancer, the family, and the health care team can work together efficiently-and effectively.Trade ReviewCancer patients who want to be fully informed participants in their own health care will find this a valuable handbook. Publishers Weekly Well written and informative. -- Susan Walker International Journal of Radiation Oncology Biology Physics 2007 This well written, up-to-date book is concise and easy to read and understand. Written in everyday language without being overly simplistic, the book provides clear explanations, examples, and practical advice that can serve as a framework for treatment decisions... 3 stars Doody's Review Service 2007Table of ContentsForeword by Edward C. Halperin, M.D.Foreword to the First Edition by Ellen L. StovallPrefaceIntroduction1. Diagnosis and Treatment: What You Can Expect2. Cancer: Where Does It Come From?3. Diagnostic Tests and Staging Studies: Gathering Information4. Making Decisions about Treatment: How Success Is Measured5. Weighing the Long-Term Risks and Benefits of Treatment6. Conventional Treatments: An Overview7. Molecular-Target Therapy8. Clincial Research Trials: What They're All About9. Clinical Case Studies: Four Patient StoriesAfterwordAppendixesA. Cancer Molecular BiologyB. Analyzing Cost-EffectivenessC. Performance Status Scoring SystemsD. Patient's ChecklistBibligraphyIndex

Read more less

Book SynopsisIn this truly inspirational memoir, Anita Moorjani relates how, after fighting cancer for almost four years, her body began shutting down—overwhelmed by the malignant cells spreading throughout her system. As her organs failed, she entered into an extraordinary near-death experience where she realized her inherent worth . . . and the actual cause of her disease. Upon regaining consciousness, Anita found that her condition had improved so rapidly that she was released from the hospital within weeks—without a trace of cancer in her body! Within these pages, Anita recounts stories of her childhood in Hong Kong, her challenge to establish her career and find true love, as well as how she eventually ended up in that hospital bed where she defied all medical knowledge. As part of a traditional Hindu family residing in a largely Chinese and British society, Anita had been pushed and pulled by cultural and religious customs since she was a little girl. After years of struggTrade Review"I have been deeply and profoundly touched by the contents of this book, and even more so by my personal relationship with Anita Moorjani, who came into my life through a series of Divinely orchestrated coincidences." - Dr. Wayne W. Dyer"Describing her ensuing near-death experience as a realm of clarity and expansiveness, 'a state of being,' Moorjani made the choice to return, and her rapid and remarkable recovery defies all medical understanding. Her psychospiritual healing, which continues to this day, was self-realization: of her own magnificence, of oneness with universal energy and with a universe comprising. This candid memoir is a cathartic testimony to the magnificence and healing capacity of every human being." - Publishers Weekly"This book is very thought provoking. Can we take the learnings, and make the changes, from someone else's Near Death Experience? Can I create for myself the same level of faith and knowing just by reading this book? Honestly, I don't think I can. But what I can do is open my mind that little bit more, take this book as another brick in building that wall of strength, and take her learnings with me on my own journey. I recommend that you do that same." - Rachel Bell"I had the pleasure of reading Anita's book after hearing her speak in Sydney, Australia at the end of January. Her NDE experience is profound. The wisdom she shares is life changing." - Cheryl Richardson"This book reminded me how important it is to live life from a place of passion rather than from a place of fear. No matter what challenge life gives us, it's really important to look for the gift in it. This book is truly amazing." - Vibrant Living with Celine

Read more less